Sun Pharma, Alembic Pharma and 1 other recall products in US
Drug makers Sun Pharmaceutical Industries, Glenmark Pharmaceuticals, and Alembic Pharmaceuticals are recalling several products in the United States over manufacturing issues, the US Food and Drug Administration (USFDA) has said in its latest Enforcement Report.
Mumbai-based Glenmark is recalling two products from the US market. Its subsidiary, Glenmark Pharmaceuticals Inc, USA, is recalling Carvedilol tablets, prescribed for heart failure, hypertension, and heart attack, in multiple strengths.
The New Jersey-based firm is recalling 55,560 units of the affected lot due to "presence of a nitrosamine, N-Nitroso Carvedilol impurity above the current acceptable intake level," the USFDA stated.
The company is also recalling 17,496 bottles of Carvedilol tablets as "results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm," it added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.